Ensuring equity with pre-clinical planning for chlamydia vaccines
Abstract Chlamydia trachomatis (Ct) remains the most common bacterial sexually transmitted pathogen worldwide, causing significant morbidity particularly among women, including pelvic inflammatory disease, ectopic pregnancy, and infertility. Several vaccines are advancing through pre-clinical and cl...
Main Authors: | Amanda L. Collar, Tegan N. Clarke, Andzoa N. Jamus, Kathryn M. Frietze |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-09-01
|
Series: | npj Vaccines |
Online Access: | https://doi.org/10.1038/s41541-023-00726-7 |
Similar Items
-
Epitope-Based Vaccines against the <i>Chlamydia trachomatis</i> Major Outer Membrane Protein Variable Domain 4 Elicit Protection in Mice
by: Amanda L. Collar, et al.
Published: (2022-05-01) -
Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis
by: Kathryn M. Frietze, et al.
Published: (2018-11-01) -
Antibodies to Variable Domain 4 Linear Epitopes of the <italic toggle="yes">Chlamydia trachomatis</italic> Major Outer Membrane Protein Are Not Associated with Chlamydia Resolution or Reinfection in Women
by: Amanda L. Collar, et al.
Published: (2020-10-01) -
Immunogenicity and Protective Capacity of a Virus-like Particle Vaccine against <i>Chlamydia trachomatis</i> Type 3 Secretion System Tip Protein, CT584
by: Everett Webster, et al.
Published: (2022-01-01) -
Making a COVID-19 vaccine that works for everyone: ensuring equity and inclusivity in clinical trials
by: Toby Pepperrell, et al.
Published: (2021-01-01)